Targovax Company
Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Investors Number:
5
Industry:
Peptides and Proteins
Total Funding:
30331820
Last Funding Type:
Grant
Last Funding Date:
2022-01-12
Headquarters:
Oslo, Oslo, Norway
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Founded Date:
2010-01-01